Glenmark Pharmaceuticals Ltd

NSE: GLENMARK · BSE: 532296 · Pharmaceuticals & Biotechnology · 39 announcements

Glenmark Pharmaceuticals Ltd news stories on ALFA NewsRead the news →

Share price: ₹2,282.30
Market cap: ₹64,412 Cr
Revenue (annual): ₹16,983 Cr
Net profit (annual): ₹1,362 Cr
P/E (TTM): 35.8×Sector 47.3×
Promoter holding: 46.65%+0.00% QoQ
FII holding: 20.89%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

30 Apr 2026 17:09 IST BSE

Glenmark Pharmaceuticals Debt & Borrowing

Glenmark Pharmaceuticals Limited confirmed it is not classified as a Large Corporate as per SEBI criteria for the financial year. Consequently, the company is not required to submit incremental debt disclosures under the circular framework. The filing reports zero outstanding borrowings as of the reporting date.

Read the filing ↗